Half-Life (Normalesrd) Hours
2.5/No data
Plasma Protein Binding %
<6
Volume Of Distribution L/Kg
0.3-0.8
Dose For Normal Renal Function
5 mg/kg weekly 2 (induction)
Second Dose
Second Dose: 5 mg/kg every 2 weeks (maintenence)
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% >55 [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
Avoid [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Avoid
Supplement For Dialysis [Recommendation Level]: Pd
PD: Avoid
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Avoid; if needed, 2 mg/kg weekly, [B]
References
Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999; 65: 21-8. [PMID: 9951427] / Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995; 39: 1247-52. [PMID: 7574510] / Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995; 171: 788-96. [PMID: 7706804]
Toxicity Notes
Dose-limiting nephrotoxicity with proteinuria, glycosuria, renal insufficiency. Nephrotoxicity and renal clearance reduced with coadministration of probenecid.